KETamine sedation as neuroprotective agent following out-of-hospital cardiac arrest (OHCA) - the KETOHCA trial.

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515987-29-00

Enrollment

282

Registered

2024-10-01

Start date

2024-12-11

Completion date

Unknown

Last updated

2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Out-of-hospital cardiac arrest

Brief summary

Neuron-specific enolase (NSE) measured 48 hours after OHCA

Detailed description

1. Death from all causes at 180 days after cardiac arrest. 2. CPC- and mRS score at hospital discharge and 180-240 days after cardiac arrest.

Interventions

DRUGPropolipid

DRUGS-ketamin "Pfizer" injektionsvæske

DRUGopløsning

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Neuron-specific enolase (NSE) measured 48 hours after OHCA	—

Secondary

Measure	Time frame
1. Death from all causes at 180 days after cardiac arrest. 2. CPC- and mRS score at hospital discharge and 180-240 days after cardiac arrest.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026